News about "chemotherapy "

Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study

Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study

IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.

Chemotherapy | 14/04/2025 | By Abha

Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer

Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer

With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.

Chemotherapy | 17/03/2025 | By Aishwarya

AstraZeneca India Secures CDSCO Approval for Durvalumab

AstraZeneca India Secures CDSCO Approval for Durvalumab

AstraZeneca Pharma India has been granted permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO).

Chemotherapy | 27/09/2024 | By Aishwarya 145

Astellas Gets EU Approval for VYLOY in Combination with Chemotherapy

Astellas Gets EU Approval for VYLOY in Combination with Chemotherapy

Astellas Pharma Inc. has announced that the European Commission (EC) has approved VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy.

Chemotherapy | 23/09/2024 | By Aishwarya 265

AstraZeneca Completes Acquisition of Fusion

AstraZeneca Completes Acquisition of Fusion

AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Chemotherapy | 06/06/2024 | By Aishwarya 172

FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer

FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer

The approval is based on the encouraging response rate and duration of response (DoR) observed in clinical studies, under the FDA's accelerated approval pathway.

Chemotherapy | 17/05/2024 | By Abha 200

Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC

Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC

Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.

Chemotherapy | 23/04/2024 | By Aishwarya 144


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members